

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>VIRALYTICS LIMITED</b> |
| <b>ABN</b>            | <b>12 010 657 351</b>     |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                 |
|----------------------------|-----------------|
| <b>Name of Director</b>    | Mr Paul Hopper  |
| <b>Date of last notice</b> | 5 December 2016 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |  |
|--|--|
| <b>Direct or indirect interest</b>   | Indirect   |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. | Kilinwata Investments Pty Ltd ACN 009 641 212<br>ATF Life Science Portfolio Managers Trust (of which Mr Hopper is a beneficiary) |
| <b>Date of change</b>  | 12 December 2017   |

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|  |   |
|--|---|
| <b>No. of securities held prior to change</b>  | <p>180,106 ordinary fully paid shares</p> <ul style="list-style-type: none"> <li>• 36,000 ordinary fully paid shares held by Ms Deborah Coleman - Mr Hopper's spouse.</li> <li>• 129,106 ordinary fully paid shares held by Kilinwata Investments Pty Ltd.</li> <li>• 15,000 fully paid shares held by Kilinwata Investments Pty Ltd ATF Life Science Portfolio Managers Trust</li> </ul> <p>766,000 unquoted options</p> <ul style="list-style-type: none"> <li>• 500,000 unquoted options held by Kilinwata Investments Pty Ltd.</li> <li>• 266,000 unquoted options held by Kilinwata Investments Pty Ltd ATF Life Science Portfolio Managers Trust</li> </ul>   |
| <b>Class</b>   | Unlisted options approved by Shareholders at the Company's AGM on 22 November 2017 – expiring 12 December 2022, exercise price \$0.747048. 66,667 vest on 12 December 2018, 66,667 vest on 12 December 2019 and 66,666 vest on 12 December 2020.  |
| <b>Number acquired</b>   | 266,000 unlisted options  |
| <b>Number disposed</b>   | Nil   |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Exercise price of \$0.747048 per share.   |
| <b>No. of securities held after change</b>   | <p>180,106 ordinary fully paid shares</p> <ul style="list-style-type: none"> <li>• 36,000 ordinary fully paid shares held by Ms Deborah Coleman - Mr Hopper's spouse.</li> <li>• 129,106 ordinary fully paid shares held by Kilinwata Investments Pty Ltd.</li> <li>• 15,000 fully paid shares held by Kilinwata Investments Pty Ltd ATF Life Science Portfolio Managers Trust</li> </ul> <p>1,032,000 unquoted options</p> <ul style="list-style-type: none"> <li>• 500,000 unquoted options held by Kilinwata Investments Pty Ltd.</li> <li>• 532,000 unquoted options held by Kilinwata Investments Pty Ltd ATF Life Science Portfolio Managers Trust</li> </ul> |

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |  |
|---|--|
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of unlisted options following shareholder approval at the Company's AGM on 22 November 2017. |
|---|--|

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder (if issued securities)</b>  | N/A |
| <b>Date of change</b>  | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| <b>Interest acquired</b>   | N/A |
| <b>Interest disposed</b>   | N/A |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   | N/A |
| <b>Interest after change</b>   | N/A |

## Part 3 – <sup>+</sup>Closed period

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>VIRALYTICS LIMITED</b> |
| <b>ABN</b>            | <b>010 657 351</b>        |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                 |
|----------------------------|-----------------|
| <b>Name of Director</b>    | Malcolm McColl  |
| <b>Date of last notice</b> | 6 December 2017 |

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | N/A  |
| <b>Date of change</b>   | 12 December 2017   |
| <b>No. of securities held prior to change</b>   | 4,100,000 unlisted options   |
| <b>Class</b>  | Unlisted options approved by Shareholders at the Company's AGM on 22 November 2017 – Options issued to Dr Malcolm McColl under the Viralytics Equity Incentive Plan. The options have an exercise price of \$0.747048 and expire on 12 December 2022. 1,250,000 of the options vest on achievement of a performance hurdle on or before 30 November 2018 and 1,250,000 of the options vest on achievement of a performance hurdle on or before 30 November 2019. |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

|   |  |
|---|--|
| <b>Number acquired</b>  | 2,500,000 unlisted options   |
| <b>Number disposed</b>  | Nil  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | N/A  |
| <b>No. of securities held after change</b>  | 6,600,000 unlisted options   |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of unlisted options following shareholder approval at the Company's AGM on 22 November 2017. |

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  |     |
| <b>Name of registered holder (if issued securities)</b>  |     |
| <b>Date of change</b>  |     |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |     |
| <b>Interest acquired</b>   |     |
| <b>Interest disposed</b>   |     |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |     |
| <b>Interest after change</b>   |     |

### Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No |
|---|----|

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|   |    |
|---|----|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | No |
| If prior written clearance was provided, on what date was this provided?                      | No |

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>Viralytics Limited</b> |
| <b>ABN</b>            | <b>12 010 657 351</b>     |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |              |
|----------------------------|--------------|
| <b>Name of Director</b>    | Peter Turvey |
| <b>Date of last notice</b> | 5 May 2017   |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Peter Turvey   |
| <b>Date of change</b>   | 11 December 2017   |
| <b>No. of securities held prior to change</b>   | 420,894 Fully Paid Ordinary Shares held by Peter Turvey & Pascale Turvey as trustees for the Katto Superannuation Fund (of which Peter Turvey is a beneficiary).<br><br>466,667 unlisted options held by Peter Turvey & Pascale Turvey as trustees for the Katto Superannuation Fund (of which Peter Turvey is a beneficiary). |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|   |   |
|---|---|
| <b>Class</b>  | Unlisted options approved by Shareholders at the Company's AGM on 22 November 2017 – expiring 12 December 2022, exercise price \$0.747048. 66,667 vest on 12 December 2018, 66,667 vest on 12 December 2019 and 66,666 vest on 12 December 2020.  |
| <b>Number acquired</b>  | 200,000 unlisted options  |
| <b>Number disposed</b>  | Nil   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | No consideration paid on issue. Exercise price of \$0.747048 per share.   |
| <b>No. of securities held after change</b>  | 420,894 Fully Paid Ordinary Shares held by Peter Turvey & Pascale Turvey as trustees for the Katto Superannuation Fund (of which Peter Turvey is a beneficiary).<br><br>666,667 unlisted options <ul style="list-style-type: none"> <li>• 466,667 unlisted options held by Peter Turvey &amp; Pascale Turvey as trustees for the Katto Superannuation Fund (of which Peter Turvey is a beneficiary).</li> <li>• 200,000 unlisted options held directly</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of unlisted options following shareholder approval at the Company's AGM on 22 November 2017.  |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |     |
|---|-----|
| <b>Detail of contract</b>                               | N/A |
| <b>Nature of interest</b>                               |     |
| <b>Name of registered holder (if issued securities)</b> |     |
| <b>Date of change</b>                                   |     |

+ See chapter 19 for defined terms.



|   |  |
|---|--|
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

**Part 3 – <sup>+</sup>Closed period**

|   |    |
|---|----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  |    |
| <b>If prior written clearance was provided, on what date was this provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>VIRALYTICS LIMITED</b> |
| <b>ABN</b>            | <b>010 657 351</b>        |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                 |
|----------------------------|-----------------|
| <b>Name of Director</b>    | Leonard Post    |
| <b>Date of last notice</b> | 1 November 2017 |

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |  |
|--|--|
| <b>Direct or indirect interest</b>   | Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. | N/A  |
| <b>Date of change</b>  | 12 December 2017   |
| <b>No. of securities held prior to change</b>  | 200,000 fully paid ordinary shares and 600,000 unlisted options.   |
| <b>Class</b>   | Unlisted options approved by Shareholders at the Company's AGM on 22 November 2017 – expiring 12 December 2022, exercise price \$0.747048. 66,667 vest on 12 December 2018, 66,667 vest on 12 December 2019 and 66,666 vest on 12 December 2020. |
| <b>Number acquired</b>   | 200,000 unlisted options   |
| <b>Number disposed</b>   | Nil  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation  | Exercise price of \$0.747048 per share.  |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

|   |  |
|---|--|
| <b>No. of securities held after change</b>  | 200,000 fully paid ordinary shares and 800,000 unlisted options.                                   |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of unlisted options following shareholder approval at the Company's AGM on 22 November 2017. |

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  |     |
| <b>Name of registered holder (if issued securities)</b>  |     |
| <b>Date of change</b>  |     |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |     |
| <b>Interest acquired</b>   |     |
| <b>Interest disposed</b>   |     |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |     |
| <b>Interest after change</b>   |     |

### Part 3 – +Closed period

|  |    |
|--|----|
| <b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b> | No |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>   | No |
| <b>If prior written clearance was provided, on what date was this provided?</b>  | No |

---

+ See chapter 19 for defined terms.